AU2002322066A1 - N-terminally truncated galectin-3 and antibodies for treating cancer - Google Patents
N-terminally truncated galectin-3 and antibodies for treating cancerInfo
- Publication number
- AU2002322066A1 AU2002322066A1 AU2002322066A AU2002322066A AU2002322066A1 AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1 AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- treating cancer
- terminally truncated
- truncated galectin
- galectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29697001P | 2001-06-08 | 2001-06-08 | |
US60/296,970 | 2001-06-08 | ||
PCT/US2002/018478 WO2002100343A2 (fr) | 2001-06-08 | 2002-06-10 | Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine-3 a utiliser dans le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002322066A1 true AU2002322066A1 (en) | 2002-12-23 |
Family
ID=23144316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002322066A Abandoned AU2002322066A1 (en) | 2001-06-08 | 2002-06-10 | N-terminally truncated galectin-3 and antibodies for treating cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1534317A4 (fr) |
AU (1) | AU2002322066A1 (fr) |
CA (1) | CA2488850A1 (fr) |
WO (1) | WO2002100343A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
EP1617849B1 (fr) | 2003-04-07 | 2008-06-18 | Prospect Therapeutics, Inc. | Composition et utilisation d'antagonistes de la galectine |
CN104198712A (zh) * | 2008-10-29 | 2014-12-10 | Bg医药股份有限公司 | 半乳凝素-3免疫测定法 |
CN102488619B (zh) | 2011-12-05 | 2014-08-06 | 上海交通大学 | 连续生产艾塞那肽微球的装置及控制微球释放速度的方法 |
US9907814B2 (en) | 2012-12-20 | 2018-03-06 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
WO2015085207A1 (fr) * | 2013-12-05 | 2015-06-11 | Texas Tech University System | Galectine-3 pour le traitement du cancer des ovaires |
JP2017507128A (ja) * | 2014-02-03 | 2017-03-16 | テキサス テック ユニヴァーシティー システムTexas Tech University System | ガレクチン−3阻害剤(gal−3m)は、プロテアソーム阻害剤と組み合わせて使用した場合、相加的な抗骨髄腫及び抗固形腫瘍効果、破骨細胞形成の減少及び器官保護と関係する |
KR20170054429A (ko) | 2014-09-03 | 2017-05-17 | 제네세규스 인코포레이티드 | 치료용 나노입자 및 관련 조성물, 방법, 및 시스템 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006407A1 (fr) * | 1985-04-23 | 1986-11-06 | Medical Biology Institute | IDENTIFICATION D'UNE PROTEINE DE LIAISON IgE PAR CLONAGE MOLECULAIRE |
US20020019009A1 (en) * | 1999-12-09 | 2002-02-14 | Roggen Erwin Ludo | High throughput screening (HTS) assays |
WO2001068123A2 (fr) * | 2000-03-13 | 2001-09-20 | La Jolla Institute For Allergy And Immunology | Activite chimiotactique de la galectine-3 a l'egard des monocytes |
-
2002
- 2002-06-10 WO PCT/US2002/018478 patent/WO2002100343A2/fr not_active Application Discontinuation
- 2002-06-10 EP EP02756157A patent/EP1534317A4/fr not_active Withdrawn
- 2002-06-10 AU AU2002322066A patent/AU2002322066A1/en not_active Abandoned
- 2002-06-10 CA CA002488850A patent/CA2488850A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1534317A4 (fr) | 2005-10-12 |
CA2488850A1 (fr) | 2002-12-19 |
WO2002100343A3 (fr) | 2005-03-17 |
EP1534317A2 (fr) | 2005-06-01 |
WO2002100343A2 (fr) | 2002-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AUPR395801A0 (en) | Antibodies against cancer | |
AU2002338015A1 (en) | Human CDR-grafted antibodies and antibody fragments thereof | |
IL200404A (en) | Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer | |
AU2002305478A1 (en) | Conjugates of reduced antibodies and biomolecules | |
AU2001290860A1 (en) | Spas-1 cancer antigen | |
AU2002364708A1 (en) | Novel compositions and methods for cancer | |
AU2002349543A1 (en) | Tumor antigens | |
AU2002351374A1 (en) | Antibodies to treat cancer | |
AU2002322066A1 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
AU2002315066A1 (en) | Methods for making antibody fragments and compositions resulting therefrom | |
AU2002308642A1 (en) | Methods for treating cancer | |
EP1469769A4 (fr) | Nouvelles compositions et methodes contre le cancer | |
AU2002337943A1 (en) | Novel compositions and methods for cancer | |
AU2002335667A1 (en) | Modified reoviral therapy | |
EP1469870A4 (fr) | Nouvelles compositions et methodes pour le traitement du cancer | |
AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer | |
AU2001257325A1 (en) | Cancer treatment | |
AU2002305138A1 (en) | Methods and materials for cancer treatment | |
AU2002360815A1 (en) | Human breast cancer biomarkers | |
AU5632500A (en) | Cancer associated antigens and uses therefor | |
AU2002366364A1 (en) | E2f and cancer therapy | |
AU2002351382A1 (en) | Combination cancer therapy | |
AU2002360454A1 (en) | Methods and compositions for treating cancer | |
AU2002363807A1 (en) | Breast cancer associated polypeptide | |
AU2000243657A1 (en) | Method of binding integrin for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |